Small Molecule Binders for Non-Canonical G-Quadruplex Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively target and inhibit undruggable proteins like N-Myc, which are involved in cancer, due to the structural similarity of G-quadruplexes, making it challenging to develop selective binders for these proteins.
Innovation Solution
Development of small molecule compounds that selectively bind to non-canonical G-quadruplex structures, such as hairpin-containing G4s, found in genes like MYCN, to reduce or inhibit N-Myc expression in cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional G-quadruplex binding compounds are used, then general G4 structures can be bound, but selectivity for non-canonical G4 structures (such as hairpin-containing G4s in MYCN) is insufficient
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (such as the pyridazinone core with particular substituent patterns) that are optimized to recognize and bind to specific local structural motifs within non-canonical G4 structures, particularly the hairpin-containing configurations found in MYCN. This localized structural optimization enables selective binding to the target G4 subtype while maintaining overall G4 binding capability.
Solution Approach 2:
The patent utilizes asymmetry through the use of chiral compounds and asymmetric molecular geometries that complement the asymmetric hairpin structure of non-canonical G4s. The chiral centers and non-planar arrangements in the compound structure allow for stereospecific interactions with the three-dimensional hairpin G4 configuration, providing structural specificity that conventional symmetric binders cannot achieve.
2Reliability
If N-Myc protein is targeted directly, then cancer treatment effect is achieved, but the protein is considered undruggable due to its transcription factor nature and structural similarity to other G4 proteins
Solution Approach 1:
The patent employs an intermediary approach by targeting the G-quadruplex DNA structure that regulates N-Myc expression, rather than attempting to directly bind the N-Myc protein itself. The compounds bind to non-canonical G4 structures in the MYCN gene region, which indirectly controls N-Myc transcription and protein levels. This intermediary target (G4 DNA) is accessible to small molecule binders, overcoming the undruggability of the N-Myc protein.
Solution Approach 2:
The patent segments the therapeutic strategy by focusing on specific regulatory elements (non-canonical G4 structures) within the larger MYCN gene locus rather than attempting to address the entire protein or all possible binding sites. This segmentation allows for selective targeting of the regulatory G4 structures that control N-Myc expression, providing a manageable and achievable therapeutic approach.
3Measurement precision
If compounds are designed to bind non-canonical G4 structures, then selectivity for MYCN is improved, but the structural complexity of the compounds increases
Solution Approach 1:
The patent applies universality by designing a core compound structure (pyridazinone with specific substituent patterns) that can bind to multiple non-canonical G4 structures with different sequences and configurations. The modular design allows the same basic molecular framework to recognize various hairpin-containing G4 motifs, reducing the need for entirely new compounds for each specific G4 variant and simplifying the overall structure-complexity relationship.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively decrease N-Myc expression and protein levels, providing a therapeutic approach for cancer treatment by targeting structurally complex G4s in DNA, thereby addressing the challenge of undruggable proteins.
Implementation Method 1
The MYC family of genes encode transcription factors that broadly govern and amplify gene expression. Three Myc proteins, c-Myc, N-Myc, and 1-Myc, contain basic helix-loop-helix (bHLH) regions that bind to DNA and directly regulate transcription.
Implementation Method 2
A new class of small molecule compounds that target non-canonical G4 structures, such as hairpin-containing G4s found in the MYCN gene, are described herein.
Data Source
AI summary
Small molecule compounds that selectively bind to non-canonical G-quadruplex (G4) structures, such as G4s in DNA found in various types of genes described herein, along with methods of using the compounds to reduce or inhibit protein (e.g., N-Myc protein) expression in cells, such as cancer cells. The compounds have a structure according to formulas described herein, or a stereoisomer, tautomer, or pharmaceutically effective salt or ester thereof.